Navigating CMC regulation when developing viral vector-based therapies

Your copy of “Navigating CMC Regulation for Viral Vector–Based Therapies” is available for download. A copy has also been sent to the email address you provided for your records.

As you review the white paper, consider how your CDMO strategy supports clinical progression as regulatory expectations increase. Early decisions around plasmid design, quality grade strategy, and documentation continuity can significantly influence future flexibility and the ability to scale with minimal rework.

The considerations outlined in this white paper are often part of a broader set of questions teams revisit as programs advance. These can include:

• - How early plasmid design choices are made
• - How quality grade expectations and documentation continuity are approached over time
• - How scalability is evaluated as clinical and manufacturing requirements evolve

Viewed together, these topics help provide context for how individual decisions made at different stages connect—so that when teams encounter additional perspectives focused on any one of these areas, they can be understood as part of the same continuum of CMC planning rather than stand‑alone decisions.